Omega Therapeutics

$5.00 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Omega Therapeutics

Omega Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. It has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

Stock Analysis

last close $4.94
1-mo return 14.4%
3-mo return 85.7%
avg daily vol. 75.31T
52-week high 31.41
52-week low 1.98
market cap. $236M
forward pe -
annual div. -
roe -263%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 87.9%
baraka

Subscribe now for daily local and international financial news

Subscribe